Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (157,387)	$ (120,314)	$ (45,704)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2,804	1,535	1,328
Non-cash lease expense	3,907	1,842	0
Net amortization of premium (accretion of discount) on marketable securities	(1,027)	1,508	380
Stock-based compensation	22,477	7,072	850
Change in fair value of preferred stock tranche liabilities	0	0	(2,507)
Change in fair value of antidilution rights	0	25,574	5,359
Change in fair value of success payments liabilities	(1,486)	7,815	2,387
Changes in operating assets and liabilities:
Collaboration receivable	(1,012)	0	0
Prepaid expenses and other current assets	(9,436)	(7,528)	(1,582)
Accounts payable	(5,216)	6,829	(1,898)
Accrued expenses and other liabilities	7,041	5,977	6,071
Success of payment liability	0	(6,250)	0
Deferred revenue	20,014	0	0
Operating lease liabilities	(3,011)	(1,940)	0
Deferred rent liability	0	0	51
Net cash used in operating activities	(122,332)	(77,880)	(35,265)
Cash flows from investing activities:
Purchases of property and equipment	(13,232)	(4,359)	(3,424)
Purchases of marketable securities	(479,401)	(371,494)	(98,484)
Maturities of marketable securities	336,678	136,755	50,781
Net cash used in investing activities	(155,955)	(239,098)	(51,127)
Cash flows from financing activities
Proceeds from issuance of Preferred Stock, net	0	93,759	92,616
Proceeds from the issuance of common stock in connection with the Vertex Agreement	39,986
Proceeds from issuance of common shares, net of commissions	286,509	285,214	0
Payment of equity offering costs	(783)	(3,630)	0
Proceeds from exercise of stock options	2,175	966	11
Proceeds from purchase of shares through employee stock purchase plan	1,069	780	0
Net cash provided by financing activities	328,956	377,089	92,627
Increase (decrease) in cash, cash equivalents and restricted cash	50,669	60,111	6,235
Cash, cash equivalents and restricted cash—beginning of period	69,567	9,456	3,221
Cash, cash equivalents and restricted cash—end of period	120,236	69,567	9,456
Supplemental disclosure of noncash investing and finnacing activities:
Property and equipment additions included in accounts payable and accrued expenses	1,706	503	86
Settlement of tranche right liability	0	0	7,064
Conversion of convertible preferred stock to common stock upon closing of initial public offering	0	218,919	0
Settlement of derivative liability by issuing common stock	0	32,490	487
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 83,417	$ 809	$ 0